180 related articles for article (PubMed ID: 23412019)
1. Management of refractory overactive bladder.
Giarenis I; Cardozo L
Minerva Ginecol; 2013 Feb; 65(1):41-52. PubMed ID: 23412019
[TBL] [Abstract][Full Text] [Related]
2. Overactive bladder: diagnosis and management.
Robinson D; Cardozo L
Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
[TBL] [Abstract][Full Text] [Related]
3. The management of overactive bladder refractory to medical therapy.
Robinson D; Giarenis I; Cardozo L
Maturitas; 2013 May; 75(1):101-4. PubMed ID: 23415926
[TBL] [Abstract][Full Text] [Related]
4. The medical management of refractory overactive bladder.
Robinson D; Giarenis I; Cardozo L
Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402
[TBL] [Abstract][Full Text] [Related]
5. Managing urinary incontinence: what works?
Giarenis I; Cardozo L
Climacteric; 2014 Dec; 17 Suppl 2():26-33. PubMed ID: 25196507
[TBL] [Abstract][Full Text] [Related]
6. Management of overactive bladder syndrome.
Srikrishna S; Robinson D; Cardozo L; Vella M
Postgrad Med J; 2007 Jul; 83(981):481-6. PubMed ID: 17621619
[TBL] [Abstract][Full Text] [Related]
7. Overactive bladder syndrome - management and treatment options.
Arnold J; McLeod N; Thani-Gasalam R; Rashid P
Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
[TBL] [Abstract][Full Text] [Related]
8. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy.
Ridout AE; Yoong W
J Obstet Gynaecol; 2010 Feb; 30(2):111-4. PubMed ID: 20143965
[TBL] [Abstract][Full Text] [Related]
9. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
Abdel-Fattah M; Chapple C; Guerrero K; Dixon S; Cotterill N; Ward K; Hashim H; Monga A; Brown K; Drake MJ; Gammie A; Mostafa A; Bladder Health UK; Breeman S; Cooper D; MacLennan G; Norrie J
Trials; 2021 Oct; 22(1):745. PubMed ID: 34702331
[TBL] [Abstract][Full Text] [Related]
10. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Giarenis I; Robinson D; Cardozo L
Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
[TBL] [Abstract][Full Text] [Related]
11. New developments in the medical management of overactive bladder.
Robinson D; Giarenis I; Cardozo L
Maturitas; 2013 Nov; 76(3):225-9. PubMed ID: 23953245
[TBL] [Abstract][Full Text] [Related]
12. Overactive bladder--a practical approach to evaluation and management.
Madersbacher H
J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
[TBL] [Abstract][Full Text] [Related]
13. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of refractory overactive bladder.
Chen LC; Kuo HC
Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
[TBL] [Abstract][Full Text] [Related]
15. Management of OAB in those over age 65.
Natalin R; Lorenzetti F; Dambros M
Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
[TBL] [Abstract][Full Text] [Related]
16. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT
J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
18. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Leong RK; De Wachter SG; van Kerrebroeck PE
Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
[TBL] [Abstract][Full Text] [Related]
19. The pharmacotherapy of overactive bladder.
Athanasopoulos A
Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
[TBL] [Abstract][Full Text] [Related]
20. Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.
Arruda RM; Castro R; Sartori M; Girão MJ
Curr Opin Obstet Gynecol; 2009 Oct; 21(5):412-4. PubMed ID: 19593131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
